Physician profile
Adam Bergin
NPI 1538537378
$3,183.34
in general payments reported to CMS, 2019-2025
27 companies · $727 in 2025
The $727 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $261 · 2022: $376 · 2023: $378 · 2024: $1,440 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,197 · Education: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,197.45 |
| Education | $348.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $619.77 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| E.R. Squibb & Sons, L.L.C. | $394.95 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $365.41 | 2021-2025 | Blu-U |
| Abbvie INC. | $212.30 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $199.71 | 2025 | Zoryve |
| Medtronic, INC. | $175.00 | 2022 | |
| Galderma Laboratories, L.P. | $159.04 | 2021-2025 | Nemluvio |
| Pfizer INC. | $155.26 | 2021-2024 | |
| Genzyme Corporation | $120.55 | 2024-2025 | |
| Lilly USA, LLC | $106.51 | 2024-2025 | Ebglyss, Taltz |
| Regeneron Healthcare Solutions, INC. | $101.28 | 2024-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $96.17 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2024 | |
| Merz North America, INC. | $54.70 | 2023 | Xeomin |
| Incyte Corporation | $49.96 | 2022-2023 | Opzelura |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $49.46 | 2024 | Vtama |
| Amgen INC. | $37.68 | 2022-2025 | Otezla |
| Ucb, INC. | $25.42 | 2025 | Bimzelx |
| Botanix Sb INC | $24.75 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $23.95 | 2024 | Ycanth |
| Leo Pharma INC. | $23.81 | 2025 | Anzupgo |
| Biofrontera INC. | $22.40 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Convatec INC. | $21.61 | 2024 | |
| Organogenesis INC. | $20.09 | 2025 | Puraply Wound Matrix |
| Allergan, INC. | $19.73 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.65 | 2021 | |
| Revance Therapeutics, INC. | $15.18 | 2024 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Bergin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.